Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19

Postgraduate Institute of Medical Education and Research

Status: Completed

Conditions: Covid19

Treatments: Diagnostic Test: LYMPHOCYTE MONOCYTE RATIO

Study type: Observational

Funder types: Other

Identifiers

NCT04534712

yet to be assigned

Details and patient eligibility

About

Corona virus disease 2019 (COVID 19), first identified in December 2019 in a cluster of population in a Chinese province, soon emerged as a pandemic, causing a huge strain on healthcare system and mortality all over the world. An ideal marker for predicting course of this illness should be easily available and reproducible; as the disease burden has spread to third world countries whose healthcare system is resource limited. Our study is aimed to study the utility of lymphocyte- monocyte ratio in the early stages to predict the progression of COVID 19 pneumonia.

Enrollment: 100 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All adults of age 18-80 years tested positive for SARS-CoV-2 reverse-transcriptase - polymerase chain reaction (rt-PCR) and presented within 7 days of symptom(s) onset

Exclusion criteria

• Pregnancy
• Sepsis
• Malignancy
• Patients on immunosuppressant therapy
• Chronic inflammatory conditions
• Cases lost to follow up

Trial design

100 participants in 2 patient groups

PROGRESSION

Description:

Cohort A with patients who progressed to next stage of illness or continue to remain in the same stage

Treatment:

Diagnostic Test: LYMPHOCYTE MONOCYTE RATIO

NON PROGRESSION

Description:

Cohort B with those who improved by two points on the ordinal scale without any further progression

Treatment:

Diagnostic Test: LYMPHOCYTE MONOCYTE RATIO